Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
IntroductionAfter the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for tumor type and active treatments. However, the data on the COVID-19 vaccine effica...
Guardado en:
Autores principales: | Deniz C. Guven, Taha K. Sahin, Saadettin Kilickap, Fatih M. Uckun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f1dab24580d04d1cb62af92af96cee69 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Fatih M. Uckun, et al.
Publicado: (2021) -
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Fatih M. Uckun, et al.
Publicado: (2021) -
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
por: Marie Forster, et al.
Publicado: (2021) -
Lymphadenopathy after the third Covid-19 vaccine
por: Can Özütemiz, et al.
Publicado: (2021) -
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
por: Alexandre Harari, et al.
Publicado: (2021)